Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Newest in this topic

  1. The impact of tau-PET in a selected memory clinic cohort: rationale and design of the TAP-TAU study 2024-10-19
  2. A feasibility study of the combination of intranasal insulin with oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk- Study rationale and design 2023-12-29
  3. A feasibility study of the combination of intranasal insulin with dulaglutide for cognition in older adults with metabolic syndrome at high dementia risk - Study rationale and design 2023-05-26

Studies

5 studies carry this tag.

Date range

2007 to 2024

Top journals

  • Mechanisms of ageing and development 2
  • Alzheimer's research & therapy 1
  • Chronobiology international 1
  • Progress in brain research 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. The impact of tau-PET in a selected memory clinic cohort: rationale and design of the TAP-TAU study

    ✓ Peer-reviewed alzhub usefulness score 69 out of 100. Alzheimer's research & therapy 2024-10-19 Biomarkers

    In TAP-TAU, we will investigate the added clinical value of tau-PET in a real-world clinical setting, including memory clinic patients with diagnostic uncertainty after routine work-up.

  2. A feasibility study of the combination of intranasal insulin with oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk- Study rationale and design

    ✓ Peer-reviewed alzhub usefulness score 50 out of 100. Mechanisms of ageing and development 2023-12-29 Drug development

    This feasibility study is anticipated to provide the basis for a multi-center large-scale randomized clinical trial (RCT) of the cognitive benefits of the combination of INI with semaglutide in individuals enriched for CVD and at high dementia risk.

  3. A feasibility study of the combination of intranasal insulin with dulaglutide for cognition in older adults with metabolic syndrome at high dementia risk - Study rationale and design

    ⚠ Retracted — do not rely on it alzhub usefulness score 16 out of 100. Mechanisms of ageing and development 2023-05-26 Drug development

    This feasibility study is anticipated to provide the basis for a multi-center large-scale randomized clinical trial of the cognitive benefits of the combination of INI with dulaglutide in individuals enriched for CVD and at high dementia risk.

  4. Repurposing anti-diabetic drugs for the treatment of Parkinson's disease: Rationale and clinical experience

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Progress in brain research 2019-11-27 Drug development

    The most pressing need in Parkinson's disease (PD) clinical practice is to identify agents that might slow down, stop or reverse the neurodegenerative process of Parkinson's disease and therefore avoid the onset of the most disabling, dopa-refractory symptoms of the disease.

  5. Ambulatory blood pressure monitoring in the prediction of cardiovascular events and effects of chronotherapy: rationale and design of the MAPEC study

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Chronobiology international 2007-01-01 Drug development

    ABPM reveals the significant circadian variation in BP, which in most individuals presents a morning increase, small post-prandial decline, and more extensive lowering during nocturnal rest.

All topic tags with their study counts